ClinConnect ClinConnect Logo
Search / Trial NCT03380299

Association of CD49d and CD44 in CLL Patients and Their Role in Prognosis

Launched by ASSIUT UNIVERSITY · Dec 15, 2017

Trial Information

Current as of July 07, 2025

Unknown status

Keywords

ClinConnect Summary

Chronic lymphocytic leukemia (CLL) is the most common type of chronic leukemia, accounting for approximately 40% of all leukemia's and mainly affecting older individuals. As it has a highly variable clinical course, identification of molecular and biological prognostic markers has provided new insights into the risk stratification of patients with CLL .

The interactions of chronic lymphocytic leukemia cells with the microenvironment in secondary lymphoid tissues and the bone marrow are known to promote CLL cell survival and proliferation . CD49d (one of biomarkers) is one of independent pro...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • All patients are newly diagnosed as CLL
  • Exclusion Criteria:
  • : patients with associated malignancies

About Assiut University

Assiut University, a prominent academic institution located in Egypt, is dedicated to advancing medical research and clinical trials that enhance healthcare outcomes. With a strong emphasis on innovation and collaboration, the university engages in a wide array of clinical studies across various disciplines, aiming to contribute valuable insights into disease prevention, diagnosis, and treatment. Assiut University's commitment to ethical research practices and rigorous scientific methodology ensures the integrity and reliability of its clinical trials, ultimately benefiting both the local community and the global medical landscape.

Locations

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials